Mariathasan et al. demonstrated that the immune-excluded phenotype might be overcome using anti-Pan-TGF-b antibody, promoting T cell priming and concentration in tumor core and restoring anti PD-L1 treatment efficacy in mouse tumor models [33•]. The gene discussed is TGFB1; the disease is neoplasm.